Page last updated: 2024-10-17

3,4-dihydroxyphenylacetic acid and Nerve Degeneration

3,4-dihydroxyphenylacetic acid has been researched along with Nerve Degeneration in 60 studies

3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.

Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.

Research Excerpts

ExcerptRelevanceReference
"Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease."1.42Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015)
"3% of the administered dose was taken up by the brain and was slowly eliminated, with a half-life of approximately 3 weeks."1.39Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice. ( Beck, M; Botham, PA; Breckenridge, CB; Butt, M; Cook, AR; Mathews, JM; Minnema, D; Smith, LL; Sturgess, NC; Tisdel, MO; Travis, KZ; Wolf, JC; Zadory, D, 2013)
"In a well-established mouse model of Menkes disease, mottled-brindled (mo-br), we tested whether systemic administration of L-threo-dihydroxyphenylserine (L-DOPS), a drug used successfully to treat autosomal recessive norepinephrine deficiency, would improve brain neurochemical abnormalities and neuropathology."1.39L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model. ( Brinster, LR; Donsante, A; Goldstein, DS; Kaler, SG; Sullivan, P, 2013)
"elegans results in dopaminergic neuron degeneration, the effects of alpha-synuclein on dopamine homeostasis and its contribution to dopaminergic neuron degeneration in C."1.36Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans. ( Cao, P; Feng, Z; Huang, Y; Moise, AR; Palczewski, K; Pehek, EA; Yuan, Y, 2010)
" Long recovery periods after MPP(+) exposure are required to distinguish between reversible or irreversible toxic and/or trophic effects."1.33Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF. ( Gramsbergen, JB; Jakobsen, B; Møller Dall, A; Rosenblad, C; Zimmer, J, 2005)
" Therefore, the aim of the present study was to examine whether the long-term administration of a commonly used herbicide, paraquat, which has already been found to induce a slowly progressing degeneration of the nigrostriatal neurons, influences mesocortical dopaminergic neurons in rats."1.33Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. ( Biedka, I; Bortel, A; Dabrowska, J; Kuter, K; Nowak, P; Ossowska, K; Rommelspacher, H; Schulze, G; Smiałowska, M; Wardas, J; Wierońska, J; Zieba, B, 2006)
" Estrogen altered the toxic effects of the second invasion of MA as indicated by a significant decrease in striatal dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations."1.33Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system. ( Dluzen, DE; Liu, B, 2006)
"Behaviour was evaluated by catalepsy tests and activity box."1.32Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003)
"Kainic acid (KA) was employed to induce neuronal lesions in the more dorsal striatum, the caudate-putamen (CP)."1.31Lesion of caudate-putamen interneurons with kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat. ( Cubeddu, LX; Guevara, BH; Hoffmann, IS; Torrico, F, 2002)

Research

Studies (60)

TimeframeStudies, this research(%)All Research%
pre-19902 (3.33)18.7374
1990's18 (30.00)18.2507
2000's29 (48.33)29.6817
2010's11 (18.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ehara, A1
Nakadate, K1
Sugimoto, H1
Yoshimoto, K1
Ueda, S1
Breckenridge, CB1
Sturgess, NC1
Butt, M1
Wolf, JC1
Zadory, D1
Beck, M1
Mathews, JM1
Tisdel, MO1
Minnema, D1
Travis, KZ1
Cook, AR1
Botham, PA1
Smith, LL1
Nordströma, U1
Beauvais, G1
Ghosh, A1
Pulikkaparambil Sasidharan, BC1
Lundblad, M1
Fuchs, J1
Joshi, RL1
Lipton, JW1
Roholt, A1
Medicetty, S1
Feinstein, TN1
Steiner, JA1
Escobar Galvis, ML1
Prochiantz, A1
Brundin, P1
Saal, KA1
Koch, JC1
Tatenhorst, L1
Szegő, EM1
Ribas, VT1
Michel, U1
Bähr, M1
Tönges, L1
Lingor, P1
Sharma, N1
Nehru, B1
Cheng, B1
Yang, X1
An, L1
Gao, B1
Liu, X1
Liu, S1
Cao, P1
Yuan, Y1
Pehek, EA2
Moise, AR1
Huang, Y1
Palczewski, K1
Feng, Z1
Marcellino, D1
Suárez-Boomgaard, D1
Sánchez-Reina, MD1
Aguirre, JA1
Yoshitake, T1
Yoshitake, S1
Hagman, B1
Kehr, J1
Agnati, LF2
Fuxe, K2
Rivera, A1
di Matteo, V1
Pierucci, M1
Di Giovanni, G1
Dragani, LK1
Murzilli, S1
Poggi, A1
Esposito, E1
Shchepinov, MS1
Chou, VP1
Pollock, E1
Langston, JW2
Cantor, CR1
Molinari, RJ1
Manning-Boğ, AB2
van Bregt, DR1
Thomas, TC1
Hinzman, JM1
Cao, T1
Liu, M1
Bing, G2
Gerhardt, GA2
Pauly, JR1
Lifshitz, J1
Donsante, A1
Sullivan, P1
Goldstein, DS1
Brinster, LR1
Kaler, SG1
Fitzmaurice, AG1
Rhodes, SL1
Lulla, A1
Murphy, NP1
Lam, HA1
O'Donnell, KC1
Barnhill, L1
Casida, JE1
Cockburn, M1
Sagasti, A1
Stahl, MC1
Maidment, NT1
Ritz, B1
Bronstein, JM1
McCormack, AL1
Thiruchelvam, M1
Thiffault, C1
Cory-Slechta, DA1
Di Monte, DA1
Ricaurte, GA1
Yuan, J1
Hatzidimitriou, G1
Cord, BJ1
McCann, UD1
Guevara, BH1
Torrico, F1
Hoffmann, IS1
Cubeddu, LX1
Srinivasan, J1
Schmidt, WJ1
Klivenyi, P1
Calingasan, NY1
Starkov, A1
Stavrovskaya, IG1
Kristal, BS1
Yang, L1
Wieringa, B1
Beal, MF1
Zaman, V1
Nelson, ME1
Rohrer, B1
Götz, ME1
Malz, CR1
Dirr, A1
Blum, D1
Gsell, W1
Schmidt, S1
Burger, R1
Pohli, S1
Riederer, P2
Jakobsen, B1
Gramsbergen, JB1
Møller Dall, A1
Rosenblad, C1
Zimmer, J1
Li, X1
Matsumoto, K1
Murakami, Y1
Tezuka, Y1
Wu, Y1
Kadota, S1
Theodore, S1
Cass, WA2
Maragos, WF1
Ossowska, K1
Smiałowska, M1
Kuter, K1
Wierońska, J1
Zieba, B1
Wardas, J1
Nowak, P1
Dabrowska, J1
Bortel, A1
Biedka, I1
Schulze, G1
Rommelspacher, H1
Liu, B2
Dluzen, DE3
Mazzulli, JR1
Mishizen, AJ1
Giasson, BI1
Lynch, DR1
Thomas, SA1
Nakashima, A1
Nagatsu, T2
Ota, A1
Ischiropoulos, H1
Sawada, H1
Hishida, R1
Hirata, Y1
Ono, K1
Suzuki, H1
Muramatsu, S1
Nakano, I1
Sawada, M1
Rojo, AI1
Cavada, C1
de Sagarra, MR1
Cuadrado, A1
Rajeswari, A1
Sabesan, M1
Kadoguchi, N1
Kimoto, H1
Yano, R1
Kato, H1
Araki, T1
Wuerthele, SM1
Moore, KE1
Lisoprawski, A1
Herve, D1
Blanc, G1
Glowinski, J1
Tassin, JP1
Pu, C1
Fisher, JE1
Cappon, GD1
Vorhees, CV1
Oishi, T1
Hasegawa, E1
Murai, Y1
Przedborski, S1
Jackson-Lewis, V1
Yokoyama, R1
Shibata, T1
Dawson, VL1
Dawson, TM1
Wesemann, W1
Solbach, M1
Nafe, R1
Grote, C1
Sontag, KH1
Jellinger, K1
Mennel, HD1
Clement, HW1
Tatton, WG1
Wadia, JS1
Ju, WY1
Chalmers-Redman, RM1
Tatton, NA1
Lan, J1
Jiang, DH1
Wei, Q1
Jurma, OP1
Andersen, JK1
Takeda, A1
Sawashita, J1
Takefuta, S1
Okada, S1
Teicher, MH1
Andersen, SL1
Campbell, A1
Gelbard, HA1
Baldessarini, RJ1
Lindner, MD1
Cain, CK1
Plone, MA1
Frydel, BR1
Blaney, TJ1
Emerich, DF1
Hoane, MR1
Youdim, MB3
Grünblatt, E1
Mandel, S1
Moy, LY1
Zeevalk, GD1
Sonsalla, PK1
Kim, H1
Jhoo, W1
Shin, E1
Disshon, KA1
Liang, SL1
Pan, JT1
Bezard, E1
Jaber, M1
Gonon, F1
Boireau, A1
Bloch, B1
Gross, CE1
Rabinovic, AD1
Lewis, DA1
Hastings, TG1
Halladay, AK1
Yue, Y1
Michna, L1
Widmer, DA1
Wagner, GC1
Zhou, R1
Fox, CM1
Gash, DM1
Smoot, MK1
Li, SW1
Lin, TS1
Minteer, S1
Burke, WJ1
Janson, AM2
Rosén, L1
Finnman, UB1
Tanganelli, S1
Morari, M1
Goldstein, M1
Crock, R1
Yamamoto, BK1
Sengstock, GJ1
Olanow, CW1
Dunn, AJ1
Arendash, GW1
Ben-Shachar, D2
Pinhassi, B1
Pasinetti, GM1
Kohama, S1
Reinhard, JF1
Cheng, HW1
McNeill, TH1
Finch, CE1
Meana, JJ1
Goiny, M1
Herrera-Marschitz, M1
Eshel, G1
Finberg, JP1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Starving for Energy - A Pilot Study to Test Ketone Derived Energy in Eating Disorders[NCT05507008]40 participants (Anticipated)Interventional2022-10-13Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for 3,4-dihydroxyphenylacetic acid and Nerve Degeneration

ArticleYear
(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
    Journal of neural transmission. Supplementum, 1996, Volume: 48

    Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Apoptosis; Cells, Cultured; Gene Express

1996
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice.
    Journal of neural transmission (Vienna, Austria : 1996), 1997, Volume: 104, Issue:4-5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Disease

1997

Other Studies

58 other studies available for 3,4-dihydroxyphenylacetic acid and Nerve Degeneration

ArticleYear
Role of neuronal nitric oxide synthase in slowly progressive dopaminergic neurodegeneration in the Zitter rat.
    Nitric oxide : biology and chemistry, 2018, 08-01, Volume: 78

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Base Sequence; Caudate Nucleus; Dopamine; Dopaminergic Neur

2018
Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
    Neurotoxicology, 2013, Volume: 37

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; B

2013
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Neurobiology of disease, 2015, Volume: 73

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease

2015
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
    Neurobiology of disease, 2015, Volume: 73

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Dependovirus; Disease Models, Animal; Do

2015
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
    Molecular neurobiology, 2016, Volume: 53, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Cytokines; Disease Models, Animal; Dopaminer

2016
Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease.
    Brain research, 2009, Aug-25, Volume: 1286

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Brain; Brain Chemistry; Chromatography,

2009
Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans.
    PloS one, 2010, Feb-19, Volume: 5, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabdi

2010
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
    Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Brain; Cell Count;

2010
Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons.
    Journal of neural transmission. Supplementum, 2009, Issue:73

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carotenoids; Disease Models, Animal; Dopamine; Functional L

2009
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
    Toxicology letters, 2011, Nov-30, Volume: 207, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid;

2011
Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat.
    Experimental neurology, 2012, Volume: 234, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atrophy; Brain Injuries; Calcium-Binding Proteins; Carrier

2012
L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.
    Annals of neurology, 2013, Volume: 73, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Triphosphatases; Animals; Antiparkinson Agents; Blood-Brai

2013
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Jan-08, Volume: 110, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Benomyl; Dopaminergic Neurons; Flow

2013
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
    Neurobiology of disease, 2002, Volume: 10, Issue:2

    Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm

2002
RETRACTED: Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
    Science (New York, N.Y.), 2002, 09-27, Volume: 297, Issue:5590

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Axons; Brain; Carrier Proteins; Corpus Str

2002
Lesion of caudate-putamen interneurons with kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat.
    Cellular and molecular neurobiology, 2002, Volume: 22, Issue:5-6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Death; Dopamine; Dose-Response Relat

2002
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
    The European journal of neuroscience, 2003, Volume: 17, Issue:12

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps

2003
Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase.
    Neurobiology of disease, 2004, Volume: 15, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Monophosphate; Animals; Brain; Brain Chemistry; Chromatogr

2004
Neurodegenerative alterations in the nigrostriatal system of trkB hypomorphic mice.
    Experimental neurology, 2004, Volume: 190, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain-Derived Neurotrophic Factor; Chromatography, High Pre

2004
Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka.
    Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animal Migration; Animals; Antioxidants; Apoptosis; Brain; Ca

2005
Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF.
    The European journal of neuroscience, 2005, Volume: 21, Issue:11

    Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Differentiation; Cell Pro

2005
Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
    Pharmacology, biochemistry, and behavior, 2005, Volume: 82, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid;

2005
Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum.
    Neuroscience, 2006, Volume: 137, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Blotting, Western; Central Nervous System Stimu

2006
Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease.
    Neuroscience, 2006, Sep-15, Volume: 141, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cerebral Cortex; Chromatography, High Pre

2006
Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
    Synapse (New York, N.Y.), 2006, Volume: 60, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Corpus Striatum; Disease Mode

2006
Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
    Neuroendocrinology, 2006, Volume: 83, Issue:5-6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Androgens; Animals; Dopamine; Dopamine Agents; Dose-Response Relatio

2006
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Sep-27, Volume: 26, Issue:39

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell D

2006
Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Journal of neuroscience research, 2007, Volume: 85, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animal

2007
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Experimental neurology, 2007, Volume: 208, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhala

2007
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
    Inflammopharmacology, 2008, Volume: 16, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Dis

2008
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
    Metabolic brain disease, 2008, Volume: 23, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat

2008
Effect of systemic and intrastriatal injections of haloperidol on striatal dopamine and DOPAC concentrations in rats pretreated by section of nigrostriatal fibres.
    The Journal of pharmacy and pharmacology, 1980, Volume: 32, Issue:7

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Feedback; Glutamate Decarboxylas

1980
Selective activation of the mesocortico-frontal dopaminergic neurons induced by lesion of the habenula in the rat.
    Brain research, 1980, Feb-03, Volume: 183, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Choline O-Acetyltransferase; Dominance, Cerebral; Dopamine;

1980
The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum.
    Brain research, 1994, Jun-27, Volume: 649, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Chromatography, High Pressure Liquid; Dopamine;

1994
Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
    Journal of neural transmission. Parkinson's disease and dementia section, 1993, Volume: 6, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat

1993
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
    Proceedings of the National Academy of Sciences of the United States of America, 1996, May-14, Volume: 93, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enz

1996
Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism.
    Journal of neural transmission. Supplementum, 1995, Volume: 46

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Dopamine; Injections; Iron;

1995
Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells.
    Journal of neuroscience research, 1997, Nov-15, Volume: 50, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Dopamine; Dopamine Agents; Hydrogen Peroxide

1997
Distribution of zinc in the substantia nigra of rats treated with 6-hydroxydopamine.
    Biological trace element research, 1998, Volume: 61, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Autoradiography; Blood-Brain Barrier; Ch

1998
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
    Neuroscience letters, 1998, May-15, Volume: 247, Issue:2-3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre

1998
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
    Behavioural brain research, 1999, Volume: 102, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa

1999
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
    Annals of the New York Academy of Sciences, 1999, Volume: 890

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Ani

1999
Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
    Journal of neurochemistry, 2000, Volume: 74, Issue:4

    Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 3,4-Dihydrox

2000
Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model.
    Brain research, 2000, Apr-17, Volume: 862, Issue:1-2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants;

2000
Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats.
    Brain research, 2000, Jun-16, Volume: 868, Issue:1

    Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Est

2000
An endogenous serotonergic rhythm acting on 5-HT(2A) receptors may be involved in the diurnal changes in tuberoinfundibular dopaminergic neuronal activity and prolactin secretion in female rats.
    Neuroendocrinology, 2000, Volume: 72, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Amp

2000
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
    The European journal of neuroscience, 2000, Volume: 12, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode

2000
Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine.
    Neuroscience, 2000, Volume: 101, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cysteine; Dopamine; Down-Regulation; Extracellular Space; G

2000
Regulation of EphB1 expression by dopamine signaling.
    Brain research. Molecular brain research, 2000, Dec-28, Volume: 85, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Cerebral Cortex; Cocaine; Cocaine-Related

2000
Neuroprotective effects of GDNF against 6-OHDA in young and aged rats.
    Brain research, 2001, Mar-30, Volume: 896, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Cell Survival; Dopamine; Glial Cell Line-Derived Neu

2001
3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
    Brain research. Molecular brain research, 2001, Sep-10, Volume: 93, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehydes; Brain; Catechols; Humans; Hydrogen Peroxide; Hydrox

2001
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
    Experimental brain research, 1992, Volume: 88, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Anesthesia, General; Animals; Benzhydryl Compounds; Central Nervous

1992
Selective subregional dopamine depletions in the rat caudate-putamen following nigrostriatal lesions.
    Synapse (New York, N.Y.), 1992, Volume: 10, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Homovanillic Ac

1992
Iron induces degeneration of nigrostriatal neurons.
    Brain research bulletin, 1992, Volume: 28, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Homovanillic Acid; Iron; Male; Nerve Degen

1992
Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
    European journal of pharmacology, 1991, Sep-17, Volume: 202, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Apomorphine; Brain Chemistry; Chlorpr

1991
Striatal responses to decortication. I. Dopaminergic and astrocytic activities.
    Brain research, 1991, Dec-20, Volume: 567, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Biomarkers; Blotting, Western; Cerebral Cortex;

1991
Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study.
    Neuroscience letters, 1991, Dec-16, Volume: 134, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Corpus Striatum; Denervation; Depression, Ch

1991
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.
    Journal of neurochemistry, 1991, Volume: 56, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Deferoxamine; Dopamine; Homovanillic Acid; Hydroxydopamines

1991